Hydroxylamine → HCID 73128072, compound
Reaction equation
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14]([OH:16])=O)[CH:10]([NH:17][S:18]([C:21]2[CH:26]=[CH:25][C:24]([O:27][CH2:28][C:29]3[C:38]4[C:33](=[CH:34][CH:35]=[CH:36][CH:37]=4)[N:32]=[C:31]([CH3:39])[CH:30]=3)=[CH:23][CH:22]=2)(=[O:20])=[O:19])[CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[NH2:40][OH:41]>>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([C:14](=[O:16])[NH:40][OH:41])[CH:10]([NH:17][S:18]([C:21]2[CH:26]=[CH:25][C:24]([O:27][CH2:28][C:29]3[C:38]4[C:33](=[CH:34][CH:35]=[CH:36][CH:37]=4)[N:32]=[C:31]([CH3:39])[CH:30]=3)=[CH:23][CH:22]=2)(=[O:20])=[O:19])[CH2:9]1)=[O:7])([CH3:3])([CH3:2])[CH3:4]Participants
3
Procedure
According to the procedure of Example 24, Step 3, 0.55 g (0.99 mmol) of 3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester and hydroxylamine afforded 4-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-yl methoxy)-benzenesulfonylamino]-piperidine-1-carboxylic acid tert-butyl ester as an amorphous white solid (0.030 g, 5.3%) after purification using reverse phase HPLC (Gilson) on a Phenomex C-18 semi-prep column, eluting an acetonitrile:water gradient. MS: 571 (M+H)+
Sources & evidence
- ORD record
- ord-f7241b0230ab422499486f03a57b2af1
- Source dataset
- uspto-grants-2009_09
- Patent number
- US07595327B2
Reaction notes
Loading…